Skip to main content

Table 3 Baseline measures of osteoarthritis and related impairment.

From: S-Adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: A double-blind cross-over trial. [ISRCTN36233495]

Variable Sequence A SAMe – Celecoxib (N = 28) Sequence B Celecoxib – SAMe (N = 29)
  N (%) N (%)
Tenderness in Knee*
None 5 (18.5%) 6 (20.7%)
Slight 9 (33.3%) 7 (24.1%)
Moderate 13 (48.1%) 14 (48.3%)
Severe 0 (0.0%) 2 (6.9%)
Swelling in Knee*
None 15 (55.6%) 6 (20.7%)
Slight 10 (37.0%) 17 (58.6%)
Moderate 2 (7.4%) 6 (20.7%)
Fluid in Knee Joint*
None 22 (81.5%) 20 (69.0%)
Slight 3 (11.1%) 7 (24.1%)
Moderate 2 (7.4%) 2 (6.9%)
Redness in Knee* 0 (0.0%) 1 (3.4%)
Walking Distance**
<1 block without pain 3 (10.7%) 3 (10.3%)
<1 block with pain 1 (3.6%) 4 (13.8%)
<1 mile without pain 1 (3.6%) 1 (3.4%)
<1 mile with pain 6 (21.4%) 7 (24.1%)
>1 mile without pain 6 (21.4%) 4 (13.8%)
>1 mile with pain 12 (42.9%) 13 (44.8%)
Basic ADL – Need Assistance with
Dressing 1 (3.6%) 0 (0.0%)
Transferring 0 (0.0%) 0 (0.0%)
Bathing 0 (0.0%) 0 (0.0%)
Toileting 0 (0.0%) 0 (0.0%)
Advanced ADL – Difficulty with
Light housework 1 (3.6%) 4 (13.8%)
Heavy housework 9 (32.1%) 16 (55.2%)
Stooping / crouching 26 (92.9%) 27 (93.1%)
Getting in/out of car 17 (60.7%) 18 (62.1%)
  1. * One patient in Sequence A had missing data. ** Multiple responses per patient were allowed. There were no statistically significant differences between the two sequences.